COMPANY

Dr. Reddy's Laboratories

Profile checked Oct 10, 2026

Keywords: Rheumatoid Arthritis Head Lice Infestation Acne Vulgaris Psoriasis Head Lice Pediculosis Rosacea Migraine Knee Osteoarthritis Follicular Lymphoma Covid19 Breast Neoplasm Female COVID-19 Prevention Acute Pain Actinic Keratosis Rapidly Escalating Migraine Episodic Migraine Medication Overuse Headache Acute Migraine Urinary Tract Infection Gonarthrosis Low Back Pain Scabies Surgical Site Infections GERD Ovarian Epithelial Cancer Recurrent Rhinosinusitis Chronic Prostatitis DFN-11 Tetrabenazine DRL_RI (Proposed rituximab biosimilar) XP23829 XP 23829 PPC-06

225Trials (company is sponsor)

Timeline

Aug 19, 2026 Trial start Phase 1: A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male Participants source ↗
Oct 3, 2023 Trial start Phase 1: Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route source ↗
Apr 19, 2021 Trial start —: Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2- source ↗
Nov 30, 2020 Trial start Phase 2/Phase 3: Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection source ↗
Aug 22, 2020 Trial start Phase 3: Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients source ↗
Apr 8, 2020 Trial start III: A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products source ↗
May 15, 2019 Trial start Phase 3: Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma source ↗
Jun 19, 2018 Trial start Phase 2: Efficacy, Tolerability, Safety, and Pharmacokinetic Study of DFN-15 source ↗
Jan 25, 2018 Trial start Phase 2: A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) source ↗
Oct 4, 2017 Trial start Phase 2: A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris source ↗
Oct 1, 2017 Trial start Phase 2: A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules source ↗
Aug 21, 2017 Trial start Phase 2: A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris source ↗
Jul 31, 2017 Trial start Phase 3: A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris source ↗
Jul 6, 2017 Trial start Phase 3: A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks source ↗
Jun 9, 2017 Trial start Phase 1: Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy Adult Subjects source ↗
Apr 15, 2017 Trial start Phase 4: Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections source ↗
Feb 14, 2017 Trial start Phase 2/Phase 3: A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period source ↗
2016-07 Trial start Phase 2: A Study to Assess the Efficacy, Safety and Tolerability of DFD-04 source ↗
2015-12 Trial start Phase 1: Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fed Conditions source ↗
2015-10 Trial start Phase 1: Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fasting Conditions source ↗
Sep 21, 2015 Trial start Phase 3: DFN-11 Injection in Episodic Migraine With or Without Aura source ↗
2015-09 Trial start Phase 2: Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine source ↗
2015-09 Trial start Phase 2: Pilot Study of DFN-11 Injection in Medication Overuse Headache source ↗
2015-09 Trial start Phase 3: A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies source ↗
Jul 28, 2015 Trial start IV: Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer source ↗

Showing 25 of 50 dated events.

Upcoming milestones

Dec 29, 2026 (ESTIMATED) · Phase 1 · A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male Participants · NCT07744828

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) Showing 50 of 225

Record	Title	Phase	Status	Start	Primary completion
NCT07744828	A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male Participants	Phase 1	Not yet recruiting	Aug 19, 2026	Dec 29, 2026 (estimated)
NCT03976102	Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma	Phase 3	Completed	May 15, 2019	Sep 28, 2022 (actual)
NCT04268771	A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products	III	Completed	Apr 8, 2020	Jan 26, 2022 (actual)
NCT06126042	Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route	Phase 1	Unknown status (ClinicalTrials.gov)	Oct 3, 2023	2024-04 (estimated)
NCT02173301	A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis	Phase 2	Completed	2014-06	2015-05 (actual)
NCT03421197	A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)	Phase 2	Completed	Jan 25, 2018	Mar 30, 2020 (actual)
NCT04529499	Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients	Phase 3	Terminated	Aug 22, 2020	Jan 22, 2021 (actual)
NCT05140655	Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-	Not listed	Unknown status (ClinicalTrials.gov)	Apr 19, 2021	Apr 19, 2022 (estimated)
NCT02061813	Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion	Phase 1	Completed	2014-01	2014-01 (actual)
NCT01518699	Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers	Phase 1	Completed	2012-01	2012-05 (actual)
NCT04640233	Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection	Phase 2/Phase 3	Unknown status (ClinicalTrials.gov)	Nov 30, 2020	2021-08 (estimated)
NCT02097485	Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation	Phase 2	Completed	2014-05	2014-09 (actual)
NCT03599193	A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris	Phase 2	Completed	Oct 4, 2017	Apr 30, 2018 (actual)
NCT03340961	A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules	Phase 2	Completed	Oct 1, 2017	Nov 7, 2018 (actual)
NCT03290027	A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris	Phase 3	Completed	Jul 31, 2017	Apr 19, 2018 (actual)
NCT03292640	A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks	Phase 3	Completed	Jul 6, 2017	May 14, 2018 (actual)
NCT03554772	Efficacy, Tolerability, Safety, and Pharmacokinetic Study of DFN-15	Phase 2	Completed	Jun 19, 2018	Aug 20, 2018 (actual)
NCT02060903	A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation	Phase 3	Completed	2014-02	2014-07 (actual)
NCT03341910	A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris	Phase 2	Completed	Aug 21, 2017	May 18, 2018 (actual)
NCT02062060	Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation	Phase 3	Completed	2014-02	2014-07 (actual)
NCT02010333	A Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of Head Lice Infestation	Phase 2	Completed	2013-04	2014-07 (actual)
NCT02062073	Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion	Phase 1	Completed	2014-01	2014-03 (actual)
NCT01336647	An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation	Phase 2	Completed	2011-04	2011-08 (actual)
NCT01907490	Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation	Phase 2	Completed	2013-03	2013-07 (actual)
NCT02296775	Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis	Phase 1/Phase 2	Completed	2014-11	2016-11 (actual)
NCT02301962	Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer	IV	Unknown status (ClinicalTrials.gov)	Jul 28, 2015	Jun 30, 2021 (estimated)
NCT03116698	A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period	Phase 2/Phase 3	Completed	Feb 14, 2017	Nov 13, 2017 (actual)
NCT02571049	Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine	Phase 2	Completed	2015-09	2016-04 (actual)
NCT02828241	A Study to Assess the Efficacy, Safety and Tolerability of DFD-04	Phase 2	Completed	2016-07	2017-01 (actual)
NCT03696329	Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fasting Conditions	Phase 1	Completed	2015-10	2015-11 (actual)
NCT03706300	Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg Under Fasting Conditions	Phase 1	Completed	2014-12	2015-01 (actual)
NCT03702855	Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fed Conditions	Phase 1	Completed	2015-12	2015-12 (actual)
NCT02569853	DFN-11 Injection in Episodic Migraine With or Without Aura	Phase 3	Completed	Sep 21, 2015	May 30, 2017 (actual)
NCT02472418	Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches	Phase 2	Completed	Jun 5, 2015	Dec 1, 2015 (actual)
NCT02583425	Pilot Study of DFN-11 Injection in Medication Overuse Headache	Phase 2	Terminated	2015-09	2016-08 (actual)
NCT02279082	DFN-02 Open Label Safety Study in Patients With Acute Migraine	Phase 3	Completed	2014-09	2015-09 (actual)
NCT03282838	Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy Adult Subjects	Phase 1	Completed	Jun 9, 2017	Aug 22, 2017 (actual)
NCT03051685	Bioavailability of DFN-15 at 3 Different Doses vs. Comparator and to Determine Dose-proportionality of DFN-15 in Fasting Healthy Adults	Phase 1	Completed	Jul 20, 2015	Aug 14, 2015 (actual)
NCT03160807	Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections	Phase 4	Unknown status (ClinicalTrials.gov)	Apr 15, 2017	2018-03 (estimated)
NCT02638831	Ketorol Gel in Gonarthrosis and Low Back Pain	Phase 4	Completed	2013-03	2013-11 (actual)
NCT02572986	A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies	Phase 3	Completed	2015-09	2016-06 (actual)
NCT01888367	Safety, Efficacy and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery	Phase 2	Completed	2013-10	2015-02 (actual)
NCT02922699	Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated Diseases	Phase 4	Completed	2013-01	2013-06 (actual)
NCT02922712	Evaluation of the Efficacy and Safety of Nise 100 mg in the Management of Osteoarthrosis (Gonarthrosis)	Phase 4	Completed	2011-03	2013-06 (actual)
NCT02865161	Amtolmetin Gaucil in Knee Osteoarthritis	Not listed	Completed	2015-02	2015-12 (actual)
NCT02260544	Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection	Phase 1	Completed	2014-07	2015-04 (actual)
NCT02712502	Levofloxacin in Bacterial Rhinosinussitis	Not listed	Completed	2014-09	2014-12 (actual)
NCT02711943	Non Interventional Study of Levofloxacin in Chronic Prostatitis	Not listed	Completed	2013-07	2014-02 (actual)
NCT02322632	Bioequivalence Study of Paricalcitol Capsules, 4 mcg Under Fasting Conditions	Phase 1	Completed	2010-11	2010-12 (actual)
NCT02322645	Bioequivalence Study of Eszopiclone Tablets, 3 mg Under Fasting Conditions	Phase 1	Completed	2008-08	2008-08 (actual)